Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
where it hit 12 out of 13 of its targets. The one area where the group fell short was diversity and inclusion. Novo Nordisk’s remuneration committee made progress on its diversity and inclusion ...
With sales of Novo Nordisk’s obesity blockbuster Wegovy more ... Novo delivered sales of 85.68 billion Danish kroner (around $12 billion), a 30% increase from the same period in 2023.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback